Vivesto Investor Relations Material
Latest events
R&D Update
Vivesto
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Vivesto
Access all reports
Segment Data
Access more data
Net sales by
Source
Sales of goods
Expenses by
Financials
Vivesto AB develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. The company offers XRP988/Apealea/Doxophos that is a drug consisting of doxorubicin encapsulated in an oil-based carrier system for injection; and Paclical/Apalutamide that is an oral formulation of a pure antiandrogen. It serves various markets through third party distributors. The company was formerly known as Oasmia Pharmaceutical AB and changed its name to Vivesto AB in March 2022. The company was founded in 1988 and is headquartered in Solna, Sweden.
Latest articles
The Birkin Bag: The Story Behind the World's Most Desired Handbag
How the Birkin bag became the world's most sought-after handbag where even the wealthy must earn the right to own one.
12 Jul 2024
The 10 Largest Semiconductor Companies in the World
Discover the top 10 semiconductor companies by market cap, exploring their innovations and business models shaping the tech landscape.
10 Jul 2024
The Rise of Nubank: Changing Latin American Finance
Discover how Nubank revolutionized Latin American banking with innovation, backed by top investors like Berkshire Hathaway.
9 Jul 2024
Ticker symbol
VIVE
Country
đžđȘ Sweden